Scarica l'app Stockscreener
6.49
3.13%
-0.21
Dopo l'orario di chiusura:
6.49
Precedente Chiudi:
$6.70
Aprire:
$6.58
Volume 24 ore:
203.02K
Relative Volume:
0.83
Capitalizzazione di mercato:
$359.39M
Reddito:
$2.22M
Utile/perdita netta:
$-40.51M
Rapporto P/E:
-5.0518
EPS:
-1.2847
Flusso di cassa netto:
$-46.53M
1 W Prestazione:
-5.12%
1M Prestazione:
-18.16%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$6.33
$6.855
Intervallo di 1 settimana:
$5.85
$7.25
Portata 52W:
$5.85
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Confronta UPB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.49 | 359.39M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Iniziato | William Blair | Outperform |
Upstream Bio Inc Borsa (UPB) Ultime notizie
Upstream Bio, Inc.’s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB) - Defense World
Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Bank of New York Mellon Corp Invests $607,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
1,660 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by US Bancorp DE - Defense World
Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution - TipRanks
William Blair Lifts Earnings Estimates for Upstream Bio - Defense World
Long UPB: Upstream Bio’s Robust Financials and Clinical Progress Signal Bullish Reversal - Invezz
Upstream Bio’s Financial Results and Strategic Progress - TipRanks
Promising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc. - TipRanks
Buy Rating for Upstream Bio: Promising Clinical Progress and Unique Drug Candidate Potential - TipRanks
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Form 10-K Upstream Bio, Inc. For: Dec 31 - StreetInsider.com
Upstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPO - Nasdaq
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business ... - Enid News & Eagle
Rhumbline Advisers Invests $275,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
AstraZeneca And GSK Put Spotlight On Nasal Polyps Space - Citeline News & Insights
Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewswire
Respiratory Disease Biotech Upstream Bio Schedules Two Major Investor Presentations in March - StockTitan
Upstream Bio (UPB) Projected to Post Earnings on Thursday - Armenian Reporter
Global Upstream Bioprocessing Equipment Market Poised for - GlobeNewswire
Upstream Bioprocessing Market Size to Reach $105.46 Bn by 2034 - BioSpace
Upstream Bio Inc (NASDAQ: UPB) – An Analysis Is What You Need - Stocks Register
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Critical Alert: Auto Industry Hit By Devastating Cyber Attacks60% Incidents Impact Millions - StockTitan
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowHere's Why - MarketBeat
Upstream Bio (NASDAQ:UPB) Trading Down 7.3%Here's What Happened - MarketBeat
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 9.4% HigherStill a Buy? - MarketBeat
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Upstream Bio (UPB) to Release Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - MarketBeat
Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA - openPR
Upstream Bio (NASDAQ:UPB) Sets New 52-Week Low – Time to Sell? - Defense World
Upstream Bio (NASDAQ:UPB) Trading Down 3.9%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 52-Week LowTime to Sell? - MarketBeat
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):